Why Veracyte, Inc.’s (VCYT) Stock Is Down 56.84%
As of Thursday, November 05, Veracyte, Inc.’s VCYT share price has dipped by 56.84%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Commentary & Analysis
Which Is a Better Investment, Veracyte, Inc. or Vir Biotechnology, Inc. Stock?
Learn more about whether Veracyte, Inc. or Vir Biotechnology, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why Veracyte, Inc.’s (VCYT) Stock Is Up 5.57%
As of Friday, October 09, Veracyte, Inc.’s VCYT share price has surged by 5.57%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Veracyte, Inc.’s (VCYT) Stock Is Down 5.33%
As of Tuesday, October 06, Veracyte, Inc.’s VCYT share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Veracyte, Inc.’s (VCYT) Stock Is Up 8.53%
As of Thursday, September 24, Veracyte, Inc.’s VCYT share price has surged by 8.53%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,949.6 | $219.9 | 55% |
|
| Shares Out (Mil) | 82.8 | 54.1 | 58% |
|
| Institutional Ownership | 99.5% | 92.9% | 89% |
|
| Float (Mil) | 79.9 | 41.4 | 56% |
|
| Beta | 1.96 | 0.95 | 91% |
|
| Avg Daily Volume (000s) | 3,191 | 522 | 86% |
|
| Price Change (52-week) |
(47.5%) | 44.7% | 21% |
|
| Growth | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 34.5% | 13.2% | 92% |
|
| Net Income (5yr) | 31.3% | (10.1%) | 86% |
|
| EPS (5yr) | 26.6% | 15.8% | 78 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.7%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | $0.446 | $1.909 | $1.943 | |
| Month Ago EPS | $0.448 | $1.913 | $1.950 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.449 | $1.906 | $1.948 | |
| Year/Year Chg | 17.4% | 132.8% | 155.1% | |
| Financials | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $582 | $38 | 42% |
|
| Net Income (TTM) (Mil) | $127 | ($44) | 63% |
|
| EPS (TTM) | $1.590 | ($1.500) | 67% |
|
| Operating Cash Flow (TTM) (Mil) | $174 | ($35) | 57% |
|
| Net Cash Flow (TTM) (Mil) | ($116) | $0 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $34 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $1,607 | $166 | 47% |
|
| Valuation | VCYT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.36 | 2.06 | 39% |
|
| P/E | 15.8 | 16.5 | 42% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.6 | 0.9 | 31% |
|
| Ratios | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 74.2% | 67.3% | 84% |
|
| Net Margin | 21.8% | (61.0%) | 80% |
|
| ROA | 8.6% | (47.5%) | 84% |
|
| ROE | 9.4% | (52.7%) | 54% |
|
| Liabilities to Assets | 8.9% | 29.6% | 5% |
|
| F-Score | 8 | 3 | 93% |
|
Passing Stock Screens
As of 11/6/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Return on Equity Screen
Factors: Quality, Growth
A screen that identifies stocks with above average earnings and sales growth that have consistently outperformed their peers measured by ROE.
| Performance Since Inception: | 12.5% |
| +/- S&P 500: | +5.1 |
